Genus annual total liabilities
2022
2023
2024
2025
2026
Genus Total Liabilities Growth & History (GNS)
Genus's total liabilities was £251.6M for fiscal 2026.
View full Genus company overviewGenus annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-06-30 | £251.6M | −£171.4M | −40.52% |
| 2025 | 2025-06-30 | £423.0M | −£51.3M | −10.82% |
| 2024 | 2024-06-30 | £474.3M | £44.7M | +10.41% |
| 2023 | 2023-06-30 | £429.6M | −£16.2M | −3.63% |
| 2022 | 2022-06-30 | £445.8M | — | — |
Genus quarterly total liabilities
Q2.25
Q4.25
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2025-12-31 | £417.4M | −£52.1M | −11.10% |
| Q4 2025 | 2025-06-30 | £423.0M | — | — |
| Q2 2025 | 2024-12-31 | £469.5M | — | — |
Genus total liabilities trends
Between the periods ended 2022-06-30 and 2026-06-30, Genus's total liabilities decreased from £445.8M to £251.6M, a change of −£194.2M. The latest reported quarter, Q2 2026, shows £417.4M.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
reported and calculated total liabilities
TickerStat uses total liabilities reported in company official filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Genus source filings ↗Community posts
Genus announces a £60 million buyback after stronger annual earnings
Genus ($GNS-LSE) announced a £60 million share-buyback program after adjusted pre-tax profit rose 35% to £100.2 million. Revenue declined 2% to £658.1 million, but stronger profitability in its pig-genetics business and improvements in its ...
